Mark Blumenkranz

Dr. Blumenkranz, M.D., MMS, is HJ Smead Professor Emeritus in the Department of Ophthalmology at Stanford University. He is a past President of the American University Professors of Ophthalmology (AUPO), a past President of the Retina Society and the Macula Society and a member of the Steering Committee of the Audacious Goals Initiative of the NEI. He was a co-founder and director of Oculeve, a dry eye company employing a neuro-modulatory approach to therapy, which was acquired by Allergan in August of 2015.